Loading stock data…
$50.12+0.02 (+0.04%)
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform.
CRISPR Therapeutics AG in the Healthcare sector is trading at $50.22 with a market capitalization of $5.6B. Wall Street consensus targets $87.50 (18 analysts), implying a +74.2% move over the next 12 months. The stock is currently near its 52-week low of $44.12, remaining 5.5% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the safe zone. Risk note: MACD remains below its signal line. The Whystock Score of 75/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $10.00M↑ | $1.00M | $0 | $0 | $0 |
| Gross Profit | -$30.27M↑ | -$44.95M↑ | -$53.70M↑ | -$57.12M↓ | -$45.15M |
| Operating Income | -$117.27M↑ | -$130.25M↑ | -$154.76M↓ | -$132.06M↑ | -$229.32M |
| Net Income | -$91.15M↑ | -$122.93M↑ | -$130.61M↓ | -$106.44M↑ | -$208.55M |
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The compan...